US Stocks Move: ImmunityBio surged on October 9 due to seminar and ANKTIVA
Bitget异动解读2026/10/09 14:15ImmunityBio Surge on October 9 Explained
Keywords: Seminar, ANKTIVA
1. On October 8, the company announced that founder and Executive Chairman Patrick Soon-Shiong will participate in a Piper Sandler virtual oncology seminar on October 16 for a fireside chat to introduce the progress of ANKTIVA and the company's immunotherapy pipeline.
2. In July, the UAE authorized the regulatory coverage of ANKTIVA to expand to 34 countries; the US Food and Drug Administration is expected to make a decision regarding the expansion of the bladder cancer label by January 6, 2027, with overseas commercialization and indication expansion for the product continuously advancing.
(Disclaimer: This content is a summary generated from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Earnings Preview | Applied Materials (AMAT.US) Q4 Results are Certain, the Real Focus is on the Missing 2027 Quantitative Guidance
Applied Materials' high growth in revenue and profit this quarter is already certain. What truly determines the stock price is the guidance for fiscal year 2027, changes in gross margin, and the marginal changes in China-related risks.
Earnings Preview | The "buyer strike" in the tech sector is spreading; if Cisco (CSCO.US) guidance falls short of expectations, it could be yet another blow to tech stock sentiment
Cisco will release its financial report on November 12. The market expects EPS to increase by 33% year-on-year and revenue to reach $18.09 billion. The focus will be on AI orders and the integration with Splunk.
Crypto prices
More
